Barclays Portfolio holdings
Barclays PLC, founded in 1690 by goldsmith bankers in London, is a British multinational financial institution headquartered in London, operating as one of the world’s oldest banks with a significant presence in investment banking, retail banking, and wealth management. Managing billions in assets, Barclays serves millions of customers globally through its retail arm (notably in the UK) and its investment banking division, which excels in trading, mergers and acquisitions, and capital markets, competing with Wall Street giants. The bank has navigated challenges like the 2008 financial crisis—opting for private funding over a government bailout—and has since focused on restructuring, digital innovation, and sustainable finance initiatives. With a rich history and a modern global footprint, Barclays remains a key player in both UK and international financial markets.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$1.6B |
| 2 |
Broadcom
AVGO
|
+$1.11B |
| 3 |
Invesco QQQ Trust
QQQ
|
+$882M |
| 4 |
JPMorgan Chase
JPM
|
+$628M |
| 5 |
Tesla
TSLA
|
+$594M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Honeywell
HON
|
+$1.54B |
| 2 |
Visa
V
|
+$1.39B |
| 3 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$1.13B |
| 4 |
Amazon
AMZN
|
+$771M |
| 5 |
Berkshire Hathaway Class B
BRK.B
|
+$575M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 45.6% |
| 2 | Technology | 19.83% |
| 3 | Financials | 7.37% |
| 4 | Consumer Discretionary | 6.6% |
| 5 | Communication Services | 5.05% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
5026
XBiotech
XBIT
$66.8M
| $3 | ﹤0.01% |
1
-20,107
| -100% | -$58.5K |
2024 Q2
4 quarters
|
|
|
BTOC
5027
Armlogi Holding Corp
BTOC
$10.3M
| $3 | ﹤0.01% |
2
| – | – |
2025 Q1
1 quarter
|
|
5028
AYTU BioPharma
AYTU
$22.5M
| $2 | ﹤0.01% |
1
| – | – |
2025 Q1
1 quarter
|
|
5029
Bridger Aerospace
BAER
$40M
| $2 | ﹤0.01% |
1
-10,412
| -100% | -$16K |
2024 Q2
4 quarters
|
|
5030
Curis
CRIS
$1.95M
| – | – |
0
| – | – |
2025 Q1
1 quarter
|
|
|
NOVA
5031
DELISTED
Sunnova Energy
NOVA
| $2 | ﹤0.01% |
3,916
-135,856
| -97% | -$30.6K |
2022 Q1
13 quarters
|
|
5032
Purple Innovation
PRPL
$9.16M
| – | – |
-2,291
| Closed | -$42.2K | – |
|
5033
Roadzen
RDZN
$104M
| $2 | ﹤0.01% |
2
-41,466
| -100% | -$41.5K |
2024 Q1
5 quarters
|
|
5034
Rafael Holdings
RFL
$80.1M
| $2 | ﹤0.01% |
1
| – | – |
2025 Q1
1 quarter
|
|
|
TPIC
5035
DELISTED
TPI Composites
TPIC
| $2 | ﹤0.01% |
2
-46,391
| -100% | -$47.2K |
2016 Q4
34 quarters
|
|
5036
VistaGen Therapeutics
VTGN
$12.5M
| $2 | ﹤0.01% |
1
| – | – |
2025 Q1
1 quarter
|
|
5037
Zura Bio
ZURA
$394M
| $2 | ﹤0.01% |
2
-55,757
| -100% | -$66.7K |
2023 Q2
8 quarters
|
|
5038
Alto Neuroscience
ANRO
$973M
| $2 | ﹤0.01% |
1
-22,507
| -100% | -$53.6K |
2024 Q1
5 quarters
|
|
|
BOLD
5039
Boundless Bio
BOLD
$59.6M
| $2 | ﹤0.01% |
2
-17,853
| -100% | -$23.7K |
2024 Q1
5 quarters
|
|
|
LONA
5040
LeonaBio Inc
LONA
$45.4M
| – | – |
0
| – | – |
2025 Q2
0 quarters
|
|
5041
Destination XL Group
DXLG
$24.1M
| $1 | ﹤0.01% |
1
-50,425
| -100% | -$55.2K |
2023 Q4
6 quarters
|
|
|
KNDI
5042
Kandi Technologies Group
KNDI
$82.4M
| $1 | ﹤0.01% |
1
| – | – |
2021 Q3
15 quarters
|
|
5043
Milestone Scientific
MLSS
$34.3M
| $1 | ﹤0.01% |
1
| – | – |
2020 Q2
20 quarters
|
|
|
NOTE
5044
DELISTED
FiscalNote
NOTE
| – | – |
-6,693
| Closed | -$50.2K | – |
|
|
OGI
5045
Organigram Holdings
OGI
$137M
| $1 | ﹤0.01% |
1
| – | – |
2022 Q1
13 quarters
|
|
5046
ProKidney
PROK
$359M
| $1 | ﹤0.01% |
1
-119,038
| -100% | -$92.7K |
2023 Q2
8 quarters
|
|
|
LNAI
5047
Lunai Bioworks
LNAI
$5.89M
| – | – |
-1,498
| Closed | -$41.8K | – |
|
5048
Relmada Therapeutics
RLMD
$384M
| $1 | ﹤0.01% |
+1
| New | +$1 |
2025 Q2
0 quarters
|
|
5049
SES AI
SES
$328M
| $1 | ﹤0.01% |
1
-160,387
| -100% | -$135K |
2023 Q2
8 quarters
|
|
|
SGMO
5050
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
| $1 | ﹤0.01% |
1
| – | – |
2013 Q2
48 quarters
|
|
Similar funds
Barclays's Q2 2025 Portfolio in Review
As of Q2 2025, Barclays held 5,681 positions worth $436B, up 24% from $353B the previous quarter. Its ten largest holdings account for 43% of the portfolio.
Barclays's Q2 2025 filing shows 461 new, 2,914 increased, 1,345 reduced and 463 closed positions. Its largest new stake was iShares MBS ETF: 4,310,047 shares worth $405M. The largest sale was Honeywell, an estimated $1.54B.
By sector, the portfolio is most concentrated in Miscellaneous at 46% of assets, up from 41% a quarter earlier, followed by Technology and Financials.
- Barclays's largest Q2 2025 buy was iShares MBS ETF: 4,310,047 shares worth $405M.
- Barclays added most to NVIDIA in Q2 2025, an estimated $1.6B increase.
- Barclays's biggest Q2 2025 reduction was Honeywell, cutting an estimated $1.54B.
- Barclays fully exited Berry Global Group, Inc. in Q2 2025, selling an estimated $173M.
- Barclays's ten largest holdings make up 43% of its $436B portfolio in Q2 2025.
- Barclays opened 461 new positions and closed 463 in Q2 2025.
- Barclays's portfolio value rose 24% quarter-over-quarter to $436B.
Based on Barclays's 13F filing for Q2 2025, filed 13 Aug 2025.